The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | The role of elotuzumab-based combinations in multiple myeloma therapy
Michael Slade, MD, Washington University School of Medicine, St Louis, MO, talks on the role of elotuzumab-based therapies in multiple myeloma, explaining that its place in the treatment algorithm of multiple myeloma remains unclear. Nevertheless, anecdotal evidence suggests that elotuzumab-based triplet combinations appear to be more beneficial in patients with slowly progressing disease. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
